Sort
21,281 grants matching “influenza”
Therapeutic antibody for RSV
$1,499,589Lawrence Michael Kauvar · Trellis Bioscience, Inc. · R44 · FY2017 · AI
Mass Spectrometry Resource for Biology and Medicine
$1,498,108Catherine E. Costello · Boston University Medical Campus · P41 · FY2014 · GM
EFFICACY OF OSELTAMIVIR IN REDUCING DURATION OF ILLNESS, VIRAL SHEDDING & TRANSIS
$1,495,758W. Abdullah Brooks · International Ctr/Diarrhoeal Dis Res · U01 · FY2007 · IP
Influenza Viral Pathogenesis
$1,495,401Jeffery Taubenberger · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Clinical evaluation of mTORC1 inhibition for geroprotection.
$1,495,146Adam R Konopka · University Of Wisconsin-Madison · U01 · FY2024 · AG
Recombinant Adenovirus Vector Vaccine Studies
$1,495,002Gary J Nabel · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
Recombinant Adenovirus Vector Vaccine Studies
$1,495,001John Mascola · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Task V32: Manufacturing and Characterization Services for Universal Influenza Vaccines.
$1,494,007Sangeetha Sagar · International Aids Vaccine Initiative · N01 · FY2023 · AI
Estimates of Influenza Vaccine Effectiveness
$1,492,854John Jay Treanor · University Of Rochester · U18 · FY2009 · IP
Vaccine and Treatment Evaluation Units
$1,492,854Nadine Georges Rouphael · Emory University · UM1 · FY2022 · AI
Annual Estimates of Influenza Vaccine Effectiveness for Preventing Laboratory-Con
$1,492,854Arnold S Monto · University Of Michigan At Ann Arbor · U18 · FY2009 · IP
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND
$1,489,636Jeffrey S Glenn · Stanford University · R01 · FY2018 · AI
Influenza Vaccine Development
$1,489,572Gary J Nabel · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
5 YEAR STRATEGY FOR REDUCING MORBIDITY & MORTALITY CAUSED BY INFLUENZA
$1,489,416Caroline Brown · World Health Organization · U51 · FY2011 · IP
Live Attenuated RSV Vaccine with Optimized Safety and Immunogenicity
$1,489,165Mark E. Peeples · Research Inst Nationwide Children'S Hosp · P01 · FY2016 · AI
Live Attenuated RSV Vaccine with Optimized Safety and Immunogenicity
$1,487,635Mark E. Peeples · Research Inst Nationwide Children'S Hosp · P01 · FY2017 · AI
Nasal microRNA during bronchiolitis and age 6y asthma phenotypes: MARC-35 cohort
$1,485,833Carlos A. Camargo · Massachusetts General Hospital · R01 · FY2020 · AI
On demand blood tests for select agent diagnosis
$1,485,259David Alland · Rbhs-New Jersey Medical School · R01 · FY2015 · AI
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses
$1,484,945Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Stanford/UNC Biomimetic U19 Research Center
$1,484,612Calvin J Kuo · Stanford University · U19 · FY2024 · AI
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses
$1,483,918Ursula Buchholz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Comparative Study of Influenza Vaccines in Adults
$1,482,290Arnold S Monto · University Of Michigan At Ann Arbor · U01 · FY2006 · AI
VACCINES ADJUVANT DEVELOPMENT PROGRAM IN INFECTIOUS AND IMMUNE MEDIATED DISEASES
$1,481,691Tyson Heilherker · Boston Children'S Hospital · N01 · FY2024 · AI
Mechanisms Of Humoral Evasion
$1,481,266Peter D Kwong · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Regulation of hepatic and systemic immune responses
$1,481,196Barbara Rehermann · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2018 · DK